This is a medical decision
Retatrutide Retatrutide represents another approach to multi-pathway activation, functioning as a triple agonist (GIP/GLP-1/glucagon) in a single molecule: Cagrilintide + GLP-1 Approach: Two separate injections Amylin + GLP-1 pathways Established safety profile for each component Flexible dose adjustment of each component Retatrutide Approach: Single injection GIP + GLP-1 + Glucagon pathways Novel triple mechanism in one molecule Fixed ratio of pathway activation Both approaches show promise for significant metabolic benefits, though they achieve multi-pathway activation through different strategies
Work with your clinician to review sources, confirm results, and assess contributing factors
6.3 Pancreatic enzyme replacement therapy Pancreatic Enzyme Replacement Therapy (PERT) substantially aids in the treatment of Exocrine Pancreatic Insufficiency (EPI) and indirectly helps improve the control of hyperglycemia (44, 45)
Patients interested in potential anti-inflammatory benefits should discuss the evidence and limitations with their GP or specialist, recognising that these medications are prescribed primarily for metabolic indications according to NICE guidance
they inhibit the activity of the pro-inflammatory enzyme 5-lipoxygenase and have demonstrated improvements in animal and human models of inflammatory diseases (including asthma, osteoarthritis, and Crohns disease) (Anonymous 2008)
